Published in Health Risk Factor Week, January 12th, 2004
In a recent study, scientists "evaluated the performance of the VERSANT HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000."
"We compared the results with population sequencing and found concordance to be in line with previous studies in treatment-experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO))," reported I. Derdelinckx and coauthors at the Catholic University of Leuven.
"Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT;...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week